The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis by Aladul, M et al.
Accepted Manuscript
The effect of new biosimilars in rheumatology and gastroenterology specialities on UK
healthcare budgets: Results of a budget impact analysis
Mohammed I. Aladul, Raymond W. Fitzpatrick, Stephen R. Chapman
PII: S1551-7411(17)30978-6
DOI: 10.1016/j.sapharm.2018.05.009
Reference: RSAP 1064
To appear in: Research in Social & Administrative Pharmacy
Please cite this article as: Aladul MI, Fitzpatrick RW, Chapman SR, The effect of new biosimilars in
rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact
analysis, Research in Social & Administrative Pharmacy (2018), doi: 10.1016/j.sapharm.2018.05.009.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare 
budgets: Results of a budget impact analysis 
Running heading: The impact of adoption of new biosimilars on NHS budget 
Mohammed I Aladul1,2, Raymond W Fitzpatrick1, Stephen R Chapman1*  
1
 School of Pharmacy, Keele University, Hornbeam Building, Newcastle-under-Lyme, Staffordshire, ST5 5BG, 
United Kingdom. 
2
 School of Pharmacy, University of Mosul, Mosul, Nineveh, Iraq. 
*
 Correspondence to: Stephen R Chapman  
School of Pharmacy, Keele University, Hornbeam Building 3.06, Newcastle-under-Lyme, Staffordshire, ST5 
5BG, United Kingdom. 
Tel: +44 (0)1782 734131 
Fax: +44 (0)1782 733326 
E-mail: s.r.chapman@keele.ac.uk 
ORICD: 0000-0002-0326-7742 
 
Compliance with ethical standards 
Funding: This study was not funded by any organisation and the researchers are independent of any funding 
bodies. 
Conflict of Interest: Mohammed I Aladul, Raymond W Fitzpatrick, Stephen R Chapman declare that they have 
no conflict of interest. 
Informed consent: Written and verbal consents were obtained from all individual participants included in the 
study. 
Ethical approval: This study approved by the Independent Peer Review Committee at Keele University and the 
Health Research Authority. 
Contributors: All authors have contributed to this study and all authors reviewed and approved the final 
version of the manuscript. MIA participated in the study design, data collection, and interpretation of results, 
prepared the manuscript draft, and performed all analytical testing and manuscript review. RWF and SRC 
participated in the study design and reviewed the manuscript and corrected the final version of the manuscript.  
Acknowledgments  
Mohammed Aladul was sponsored by the Higher Committee for Education Development in Iraq. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
1 
 
The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare 1 
budgets: Results of a budget impact analysis 2 
Abstract  3 
Background: The approval of new biosimilars of infliximab, etanercept and adalimumab by the European 4 
Medicines Agency is expected to produce further cost savings to the healthcare system budget.  5 
Objectives: This study aimed to estimate the budget impact of the introduction of new biosimilars Flixabi®, 6 
Erelzi®, Solymbic®, Amgevita® and Imraldi® in rheumatology and gastroenterology specialities in the UK. 7 
Methods: A published budget impact model was adapted to estimate the expected cost savings following the 8 
entry of new biosimilars Flixabi®, Erelzi®, Solymbic®, Amgevita® and Imraldi® in the UK over three-year time 9 
horizon. This model was based on retrospective market shares of biologics used in rheumatology and 10 
gastroenterology which were derived from DEFINE Software and healthcare professional perspectives. 11 
Results: The model predicted that infliximab and etanercept biosimilars would replace their corresponding 12 
reference agents by 2020. Adalimumab biosimilars were predicted to achieve 19% of the rheumatology and 13 
gastroenterology market by 2020. Without the introduction of further biosimilars, the model predicted a 14 
reduction in expenditure of £44 million on biologics over the next three years. With the entry of Flixabi®, 15 
Erelzi®, Solymbic®, Amgevita® and Imraldi® the model estimates cumulative savings of £285 million by 2020. 16 
Conclusions: The introduction of new infliximab, etanercept and adalimumab biosimilars will be associated 17 
with considerable cost savings and have a substantial favourable impact on the UK NHS budget. The number of 18 
biosimilars and time of entry of is critical to create competition which will result in maximum cost savings. 19 
 20 
Key points 21 
• Previous budget impact analyses predicted a considerable cost savings from the introduction of infliximab and 22 
etanercept biosimilars. 23 
• This budget impact analysis estimated the impact of the introduction of new (upcoming) biosimilars in 24 
rheumatology and gastroenterology specialities in UK. 25 
• This budget impact analysis is unique in that it uses market reaction to previously marketed biosimilars from 26 
retrospective (real-life) data and healthcare professionals’ perspectives. 27 
 28 
Keywords 29 
Budget impact analysis; biosimilar; rheumatology; gastroenterology   30 
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1. Introduction 31 
Rheumatic disorders (RD) including rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic 32 
arthritis (PA), and inflammatory bowel disease (IBD) including ulcerative colitis (UC) and Crohn’s disease 33 
(CD) are chronic inflammatory autoimmune diseases. According to the National Rheumatoid Arthritis Society 34 
and the British Gastroenterology Association 690,000 and 240,000 people in the UK are living with RD and 35 
IBD respectively [1, 2]. RA is the leading cause of pain and disability, costing the National Health Service 36 
(NHS) £5 billion a year [1]. The additional cost to the economy of sick leave and work-related disability has 37 
been estimated at between £3.8 and £4.75 billion per year [3]. IBD costs the NHS around £900 million annually 38 
[4]. 39 
Biological disease-modifying antirheumatic drugs (bDMARDs) and biological disease-modifying anti-40 
inflammatory bowel disease drugs (bDMAIDs), as monoclonal antibodies and soluble receptors, are well 41 
established as the most effective agents for treating patients with severe RD and moderate to severe IBD and for 42 
those unresponsive to conventional agents [5, 6]. Given the nature of RD and IBD, both bDMARDs and 43 
bDMAIDs are considered chronic therapy and are often continued indefinitely upon commencement unless 44 
there is either loss of response or side effects [7]. bDMARDs, and bDMAIDs are expensive and contribute 45 
highly to RD and IBD bills [8]. 46 
Biosimilars are potentially cost-effective alternatives to reference biological medicines and represent a cost 47 
containment tool to reduce the biologics bill [9]. Up to September 2017, three biosimilars of infliximab 48 
(Inflectra® and Remsima®) and etanercept (Benepali®) were in use in the UK for RD and IBD. Recently, an 49 
additional infliximab biosimilar (Flixabi®) and an etanercept biosimilar (Erelzi®) received market authorisation 50 
in the UK. Three adalimumab biosimilars (Solymbic®, Amgevita® and Imraldi®) were licenced by the European 51 
Medicine Agency (EMA) in March and August 2017 and launch is anticipated in the UK market immediately 52 
following the patent expiry of branded (reference) adalimumab (Humira®) in October 2018 [10, 11]. The 53 
behaviour of the biologics market following the launch of infliximab and etanercept biosimilars suggests that the 54 
introduction of adalimumab biosimilars will provoke competition with subsequent savings. A previous survey of 55 
healthcare professionals (HCPs) showed that there are subtle differences between specialities views on 56 
biosimilars with different uptake patterns [12].  57 
Budget impact analysis (BIA) is an estimation of the potential financial impact of the adoption of a new 58 
intervention (medicine) into health systems such as the UK NHS over a short to medium time horizon [13, 14]. 59 
BIA provides health service managers and commissioners (payers) with information to support budget planning 60 
and effective resources allocation [15].  61 
A survey of the literature revealed that budget impact analyses have been performed to estimate cost savings 62 
associated with the entry of infliximab and etanercept biosimilars before and after their market entry at national 63 
and international levels [16-25]. The majority of these budget impact analyses were based on third-party payer 64 
perspective (public health systems, payers, patients, and healthcare professionals). None of these analyses were 65 
conducted on adalimumab biosimilars or the impact of the entry of new infliximab and etanercept biosimilars in 66 
RD and IBD markets. Furthermore, none of these studies has factored in the impact of competition on reference 67 
biologic and biosimilars prices. To fill this gap in knowledge, the aim of this study was to estimate the potential 68 
cost savings associated with the introduction of adalimumab, etanercept and infliximab biosimilars (Solymbic®, 69 
Amgevita®, Imraldi®, Erelzi® and Flixabi®) for the treatment of RD and IBD on the NHS budget in the UK for 70 
the next three years (2018-2020). As the time horizon for the BIA should be until the proposed drug has reached 71 
a stable market share [14], it is expected that adalimumab biosimilars would reach a stable market share by 72 
2020. Since there are already biosimilars of infliximab and etanercept on the market, it is anticipated that the 73 
market share for the new biosimilars would be stable before then. 74 
2. Methods 75 
2.1. Healthcare professional perspectives 76 
Healthcare professionals (HCPs) (consultants, pharmacists and nurses) in rheumatology and gastroenterology 77 
specialities who are involved in prescribing, managing and procuring biological medicines including biosimilar 78 
medicines were asked for the expected price reduction offered by newly launched biosimilars.  79 
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2.2. Budget impact analysis model 80 
A published Microsoft Excel-based static budget impact model developed by Mauskopf et al., [14] was 81 
modified and updated to estimate the financial impact of the introduction Solymbic®, Amgevita®, Imraldi® 82 
(adalimumab biosimilars), Erelzi® (etanercept biosimilar) and Flixabi® (infliximab biosimilar) for the treatment 83 
of RD and Solymbic®, Amgevita®, Imraldi® and Flixabi® for the treatment IBD in the UK. A one-year time 84 
horizon (reference case scenario) was built from current (in 2017) real-life market shares and prices for each 85 
biological drug (the reference and the biosimilar), in rheumatology and gastroenterology specialities, derived 86 
from the DEFINE Software [26]. A three-year time horizon BIA model for the years 2018-2020 was created 87 
based on extrapolation of the utilisation trends and costs from data on the market reaction to existing biosimilars 88 
of bDMARDs and bDMAIDs. The perspective of HCPs in rheumatology and gastroenterology was also 89 
included in the BIA model (Table 1).  90 
2.3. Population 91 
Data on adult population, disease-specific incidence and prevalence, percentage of patients who were eligible to 92 
receive bDMARDs and bDMAIDs in the UK were derived from the published literature and NHS reports (Table 93 
2) [27-33]. The size of the adult population in the UK (eligible population) was 50,192,000 with 0.8% annual 94 
population growth rate [34]. Applying the eligibility criteria in Table 1 resulted in estimation of 626,847 patients 95 
with a rheumatological disease and 230,883 patients with a gastroenterological disease. The estimated number 96 
of adult patients receiving biological medicine is the sum of (adult population multiplied by the incidence of a 97 
specific disease multiplied by the percentage of eligible patient population for biological treatment (Table 2)) 98 
plus (adult population multiplied by the prevalence of a specific disease multiplied by the percentage of eligible 99 
patient population for biological treatment (Table 2)).  100 
Table 1 Flow diagram for an analysis of the budget impact of infliximab, etanercept and adalimumab biosimilars in 101 
rheumatology and gastroenterology specialities in the UK 102 
1. Eligible Population 
 
 Adult population of UK  Adult population of UK 
 ↓  ↓ 
 Incidence of disease   Prevalence of disease 
 ↓  ↓ 
 Percentage of adult eligible for 
bDMARDs or bDMAIDs 
 Percentage of adult eligible for 
bDMARDs or bDMAIDs 
 ↓  ↓ 
 Total number of adult patient receiving bDMARDs or bDMAIDs 
  ↓ 
2. Time horizon  Annual costs for three years 
  ↓  ↓ 
3. Current and future 
treatment mix 
 bDMARDs or bDMAIDs without the 
introduction of Flixabi®, Erelzi®, 
Solymbic®, Amgevita® and Imraldi®* 
 
 
bDMARDs or bDMAIDs with the 
introduction of Flixabi®, Erelzi®, 
Solymbic®, Amgevita® and Imraldi® 
  
  
  ↓  ↓ 
4. Cost  Average net prices  Forecasted price 
  ↓  ↓ 
5. Budget impact  Without Flixabi®, Erelzi®, 
Solymbic®, Amgevita® and Imraldi® 
 With Flixabi®, Erelzi®, Solymbic®, 
Amgevita® and Imraldi® 
* Flixabi® (infliximab biosimilar), Erelzi® (etanercept biosimilar) and Solymbic®, Amgevita®, Imraldi® (adalimumab biosimilars) 103 
 104 
Table 2 Percentage of incidence and prevalence of rheumatic disorders and IBD 105 
Population Ulcerative colitis 
[27] 
Crohn’s Disease 
[28] 
Rheumatoid 
Arthritis [29, 
30] 
Ankylosing 
Spondylitis [31, 
32] 
Psoriatic 
Arthritis [33] 
Prevalence 0.24% 0.20% 0.86% 0.2% 0.15% 
Incidence 0.01% 0.01% 0.015% 0.0069% 0.017% 
Percentage patient 11.5%* 19%** 10%* 20%* 2.4%* 
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population eligible for 
biological treatment 
Estimated total number 
of adult patients 
receiving biological 
treatment 
14,603 20,027 43,918 20,770 2,012 
* Eligible patient population for biological treatment taken from the literature [refences 27, 30, 32, 33] 106 
** Eligible patient population for biological treatment is the sum of multiplication of percentage of adults with moderate or severe Crohn’s 107 
disease (40%) multiplied by the percentage of patients in whom conventional treatment is ineffective or where they cannot tolerate it (50%) 108 
multiplied by the percentage of adults with moderate or severe Crohn’s disease who require anti-tumour necrosis agent (95%) [reference 28] 109 
2.4. Market shares and cost 110 
Retrospective secondary care market shares of bDMARDs (adalimumab, etanercept, infliximab, certolizumab 111 
pegol, golimumab, abatacept and tocilizumab) in rheumatology specialities (Figure 1) and bDMAIDs 112 
(adalimumab, infliximab, golimumab and vedolizumab) in gastroenterology specialities (Figure 2) were derived 113 
from the DEFINE Software from January 2014-October 2017. The DEFINE Software is a NHS prescribing 114 
database of medicines usage covering over 90% of acute NHS hospitals as well as Specialist Centres and Mental 115 
Health Trusts throughout the UK [26]. The UK Medicine Optimisation Dashboard was also visited to view the 116 
percentage of uptake of existing biosimilars and degree of saturation in each Trust [35]. Secondary care prices 117 
were the average net prices for each product (reference biologic and biosimilar) across all trusts within the 118 
DEFINE Software including value-added tax. Annual acquisition costs only were included in this analysis. 119 
Administration and therapy monitoring costs were not included (assumed to be the same) since no switching 120 
between different molecules was anticipated. Modelling of the switching was limited to reference biological 121 
medicine / biosimilar for the same molecule using utilisation patterns from a previous study [16]. 122 
2.5. Scenario analysis 123 
Retrospective market analyses of existing anti-tumour necrosis (TNF) biosimilars (from DEFINE Software) 124 
revealed that the UK market reacted in a complex way to the availability of these biosimilars as reference 125 
biological products reduced their prices in response to the availability of less expensive biosimilars. The model 126 
applied to the forward projection for the three current brands of adalimumab, etanercept and infliximab assumed 127 
the same level of discounting, i.e.; 10% reduction in the first year of competition, 20% in the second year [16], 128 
35% in the third year (actual data on infliximab from DEFINE Software in October 2017). For the fourth year a 129 
discount of 50% was assumed. For the bDMARDs/bDMAIDs biosimilars, a similar retrospective analysis 130 
identified an average 33% discount at launch [16], and continued to decrease in response to competition by 15% 131 
per year on average. The model assumed this would plateau at 40% of the biosimilars marketing price at year 5 132 
and beyond. These assumptions were further supported by a report in May 2017, in which Remsima had 133 
actually been sold to the NHS at prices 40% - 50% lower than the list price of Remicade® [36]. Despite price 134 
reductions of reference biological medicines and biosimilars infliximab and etanercept, the prices of other 135 
biologics did not change [16]. 136 
Biosimilars penetrated the market gradually, achieving 10% of the molecule market in the first year, 35% in the 137 
second year and 65% in the third year [16]. Uptake in the fourth year and beyond was modelled at an average of 138 
90%, based on figures from the commissioning framework for biological medicines report in September 2017 139 
[37].  140 
To examine the impact of the introduction of Flixabi®, Erelzi®, Solymbic®, Amgevita® and Imraldi® on the UK 141 
budget the first, reference case, scenario considered a market forecast in which no new biosimilars were 142 
launched. Four further sequential analyses were conducted all based on 2017 market share and prices. The first 143 
scenario was modelled on only infliximab biosimilar (Flixabi®) entering the market at a discount of 50% 144 
compared to existing infliximab biosimilars (Inflectra® and Remsima®) in RD and IBD market (based on actual 145 
costs in the DEFINE database at October 2017) (Table 3).  146 
The second scenario (etanercept biosimilar (Erelzi®) entry) assumed at a discount of 10% compared to available 147 
etanercept biosimilar (Benepali®) in RD (based on the results of the qualitative interviews with HCPs in 148 
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rheumatology). The third scenario (adalimumab biosimilars entry) assumed that adalimumab biosimilars would 149 
be available at a discount of 33% compared to branded adalimumab (Humira®) in RD and IBD (based on the 150 
previous market behaviour of bDMARDs biosimilars and HCPs opinions). The fourth scenario (all new 151 
biosimilars entry) examined the budget impact of the availability of all new biosimilars in RD and IBD at the 152 
suggested prices and molecule market shares used in scenarios one to three. Linear regression analysis was used 153 
to predicted market shares of existing reference biologic and biosimilar bDMARDs and bDMAIDs uptake 154 
patterns and extrapolated forward to 2020 (Table 3). 155 
Table 3 Model assumptions 156 
No. Model name Assumptions Biosimilars entry prices Total 
biosimilars 
market share 
per molecule 
Biosimilars 
price 
reduction 
Reference 
annual price 
reduction 
0 Reference 
case scenario  
No new 
biosimilars were 
launched 
Already in use 
biosimilars (Remsima, 
Inflectra and Benepali) 
1st year 10%  
2nd year 35%  
3rd year 60%  
4th year 90% 
1st year 33% 
of reference 
price. 
2nd - 4th year 
15% 
reduction 
per year. 
5th year and 
beyond 40% 
of the 
reference 
price. 
1st year 
10%  
2nd year 
20%  
3rd year 
35%  
4th year 50% 
1 Infliximab 
biosimilar 
case scenario 
Entry of Flixabi® 
to RD and IBD 
markets 
Flixabi® actually 
marketed at a discount 
of 50% compared to 
existing infliximab 
biosimilars (Inflectra® 
and Remsima®) in RD 
and IBD market 
1st year 10%  
2nd year 35%  
3rd year 60%  
4th year 90% 
2nd - 4th 
year 15% 
reduction 
per year. 
Already 
plateaued at 
50% 
2 Etanercept 
biosimilar 
case scenario 
Entry of Erelzi® to 
RD market 
Erelzi® marketed at a 
discount of 10% 
etanercept biosimilar 
(Benepali®) in RD 
1st year 10%  
2nd year 35%  
3rd year 60%  
4th year 90% 
2nd - 4th 
year 15% 
reduction 
per year. 
2nd year 
20%  
3rd year 
35%  
4th year 
50% 
3 Adalimumab 
biosimilars 
case scenario 
entry of 
Solymbic®, 
Amgevita® and 
Imraldi® to RD 
and IBD markets  
Adalimumab 
biosimilars marketed at 
a discount of 33% 
compared to branded 
adalimumab (Humira®) 
in RD and IBD 
1st year 10%  
2nd year 35%  
3rd year 60%  
4th year 90% 
1st year 33% 
of reference 
price. 
2nd - 4th year 
15% 
reduction 
per year. 
5th year and 
beyond 40% 
of the 
reference 
price. 
1st year 
10%  
2nd year 
20%  
3rd year 
35%  
4th year 50% 
4 All new 
biosimilars 
case scenario 
Entry of Flixabi®, 
Erelzi®, 
Solymbic®, 
Amgevita® and 
Imraldi® to RD 
and IBD markets 
Entry of all biosimilars 
in scenarios one to 
three,  
1st year 10%  
2nd year 35%  
3rd year 60%  
4th year 90% 
This the 
sum 
modelled 
prices 
scenarios 1-
3 
As in 
scenarios 1-
3 
 157 
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2.6. Sensitivity analysis 158 
One-way sensitivity analyses were used to test the sensitivity of the model assumptions. Parameters varied in the 159 
sensitivity analyses included market uptake of biosimilars (±10 %), discount on the price of biosimilars (±10 160 
%), the total number of patients treated with biologics (±10 %) for the fourth (all biosimilars entry) scenario 161 
(Figure 3). An internal validation of the model has been performed by the authors. 162 
3. Results 163 
3.1. Market shares 164 
Figures 1 and 2 show retrospective and forecasted market shares of biologics before and after the entry of 165 
biosimilars in rheumatology and gastroenterology specialities respectively. During 2014, no 166 
bDMARDs/bDMAIDs biosimilars were in use in UK.  167 
Figure 1 shows that the percentage of utilisation of infliximab biosimilars increased gradually from 1% in 2015 168 
to 6% in 2017. The percentage of utilisation of etanercept biosimilar (Benepali®) increased from 3.4% in 2016 169 
to 12.6% in 2017. It would be expected that with the entry of new infliximab and etanercept biosimilars, these 170 
would replace their corresponding branded reference products by 2020 rather than existing molecule biosimilars 171 
(Figure 1). Similarly, it would be expected following the entry of adalimumab biosimilars in 2018 that these 172 
biosimilars would achieve 19.4% of the RD market by 2020. 173 
Interestingly, the RD market share of infliximab (reference biologic and biosimilars) decreased from 12% in 174 
2014 to 9.7% in 2017 and is expected to decrease gradually to 8% by 2020. Similarly, the RD market share of 175 
etanercept (reference biologic and biosimilar) decreased from 35% in 2014 to 32% in 2017 and is expected to 176 
decrease gradually to 30% by 2020. Therefore, it would be expected that following the introduction of 177 
adalimumab biosimilars in 2018, the percentage of utilisation of adalimumab (reference biologic and 178 
biosimilars) would decrease from 34% in 2017 to 32% by 2020 (Figure 1). In contrast, the RD market share 179 
percentage of golimumab (Simponi®), certolizumab (Cimzia®), tocilizumab (RoActemra®) and abatacept 180 
(Orencia®) increased from 18% in 2014 to 25% in 2016 and plateaued in 2017. Our model predicts the market 181 
share of these agents would increase gradually to 30% by 2020 (Figure 1).  182 
Figure 2 shows that the percentage of utilisation of infliximab biosimilars increased from 11.5% in 2015 to 183 
43.5% in 2017 in the IBD market. It would be expected that this utilisation would further increase with the entry 184 
of new infliximab biosimilar to replace branded infliximab (Remicade®) in the IBD market by 2020. Similarly, 185 
it would be expected following the entry of adalimumab biosimilars in 2018 that these biosimilars would 186 
achieve 19% of the IBD market by 2020 based on the model described in section 2.5 (Figure 2). In a similar way 187 
to the RD market, the IBD market share of infliximab (reference biologic and biosimilars) decreased from 66% 188 
in 2014 to 54% in 2017 and is expected to decrease gradually to 48.35% by 2020. Therefore, it would be 189 
expected that following the introduction of adalimumab biosimilars in 2018, the IBD market share of 190 
adalimumab (reference biologic and biosimilars) would decrease from 36% in 2017 to 31.85% by 2020 (Figure 191 
2). 192 
In contrast, the IBD market share of golimumab (Simponi®) and vedolizumab (Entyvio®) increased from 1.5% 193 
in 2014 to 10% in 2017. Our model predicts the percentage of utilisation of these agents would increase 194 
gradually to 19.8% by 2020 (Figure 2).  195 
3.2. Scenario analysis 196 
Reference case and biosimilars entry scenarios analyses were performed to examine the budget impact of entry 197 
of new biosimilars in RD and IBD markets as described in section 2.5. Scenario findings are presented in Table 198 
4. The reference case model assessed the budget impact if no new biosimilars enter the RD and IBD markets. 199 
The cumulative impact of this model was a reduction in expenditure by £48,360,678 in RD and an increase of 200 
£4,359,509 in IBD for the next three years. 201 
Flixabi®, Erelzi® and adalimumab biosimilars entry models assessed the budget impact of the entry of each 202 
biosimilar separately in the RD and IBD markets. The impact of the introduction of adalimumab biosimilars was 203 
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found to be associated with highest savings compared to Flixabi® and Erelzi® entry (Table 4). The net budget 204 
impact of the entry of these new biosimilars was two times higher in RD compared to IBD (Table 4). 205 
 206 
Table 4 Budget impact of adoption of new biosimilars in rheumatology and gastroenterology specialities in UK in British 207 
pounds sterling 208 
  Year 1 
(2018) 
Year 2 
(2019) 
Year 3 
(2020) 
Total 
Reference case (no new biosimilars 
entry) 
RD -30,987,173 -20,489,593 3,116,088 -48,360,678 
IBD -6,573,865 2,202,941 8,730,433 4,359,509 
Infliximab biosimilar (Flixabi®) entry RD -380,046 -694,037 -1,053,356 -2,127,439 
IBD -1,287,986 -1,825,976 -3,007,921 -6,121,883 
Etanercept biosimilar (Erelzi®) entry RD -671,772 -1,515,143 -6,309,710 -8,496,625 
IBD - - - - 
Adalimumab biosimilars (Solymbic®, 
Amgevita® and Imraldi®) entry 
RD -25,396,052 -59,854,051 -91,623,114 -176,873,217 
IBD -14,219,076 -31,449,623 -45,499,677 -91,168,376 
All new biosimilars entry (Flixabi®, 
Erelzi®, Solymbic®, Amgevita® and 
Imraldi®) 
RD -26,447,870 -62,063,232 -98,986,181 -187,497,283 
IBD -15,507,063 -33,275,599 -48,507,599 -97,290,261 
 209 
3.3. Sensitivity analysis 210 
The results of sensitivity analysis for all biosimilars entry in RD are shown in Figure 3. The highest total impact 211 
on savings was calculated by changing biosimilars market uptake.  212 
4. Discussion 213 
Our BIA estimated the impact of the introduction of new biosimilars in RD and IBD on the NHS healthcare 214 
budget in the UK. Our study is the first calculating savings realised from the introduction of adalimumab 215 
biosimilars in rheumatology and gastroenterology specialities in the UK. This BIA model was based on the 216 
previous UK market behaviour as a result of the introduction of infliximab and etanercept biosimilars 217 
(Inflectra®, Remsima® and Benepali®) from retrospective data (DEFINE Software), data from the medicine 218 
optimisation dashboard about infliximab and etanercept biosimilars uptake in UK acute Trusts, and the results 219 
from HCPs interviews. The results of this analysis showed that the introduction of new infliximab, etanercept 220 
and adalimumab biosimilars will deliver a considerable cost saving to the NHS (Table 4). These savings are in 221 
line with the NHS aims and vision that introduction of biosimilars has the potential to realise savings of at least 222 
£200-300 million per year by 2020/21 [37]. 223 
According to NICE guidelines, with the availability of more than one suitable treatment option, the less 224 
expensive agent including biosimilars should be chosen [5]. Infliximab and etanercept biosimilars have been 225 
considered as first-line agents in IBD and RD; respectively by some regional/local medicines management 226 
group/local formularies [38, 39]. The relatively rapid penetration of infliximab and etanercept biosimilars in 227 
IBD and RD market; respectively, (Figures 1 and 2) indicates that these products are prescribed for stabilised 228 
and biological naïve patients. This inference is further supported by the British Society of Gastroenterology 229 
statement (in 2016) which supported both initiation and switching to infliximab biosimilars and early data from 230 
the British Society for Rheumatology biologics register for RA (in 2017) that RD patients are actively being 231 
switched to infliximab and etanercept biosimilars for cost reasons [40, 41]. 232 
An unexpected market response to the entry of biosimilars was seen during 2015-2016, when the market share 233 
of infliximab and etanercept (reference biological product and biosimilars) decreased following the introduction 234 
of their corresponding biosimilars (Figures 1 and 2). In contrast, the market share of biologics not subjected to 235 
biosimilars competition such as golimumab, certolizumab, tocilizumab, abatacept and vedolizumab increased 236 
(Figure 1). This may be due to treatment failure, inadequate response, inability to tolerate, contraindication or 237 
adverse effect with other biologics and require switching to another molecule. For example, 5% of IBD patients 238 
cannot tolerate treatment with infliximab or adalimumab, and these biologics were ineffective in 41% of CD 239 
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patients [28]. Similarly, 5.9% of RA patients have a contraindication or cannot tolerate anti-TNFs such as 240 
infliximab and adalimumab [42]. Moreover, some physicians’ reluctance and/or concerns to prescribe 241 
biosimilars may also influence their choice of treatment from molecules with biosimilars to agents not subjected 242 
to biosimilars competition [43]. Switching among bDMARDs/bDMAIDs depends on the clinician’s decision to 243 
a second agent or an agent with a different mechanism of action [44]. Therefore, it would be expected that with 244 
the entry of more biosimilars (Flixabi® and Erelzi®) at the beginning of 2018 and adalimumab biosimilars late at 245 
the end of 2018, the market share of adalimumab (reference biological product and biosimilars) would also 246 
decrease following the introduction of adalimumab biosimilars. The increased market share of agents not 247 
subjected to biosimilars competition, i.e. reference biological agents which are more expensive, as well as 248 
population growth, was responsible for the increased expenditure in the IBD reference case scenario and 249 
offsetting of savings from existing and new biosimilars in all other scenarios (Table 4) This factor was not taken 250 
into account in other BIAs.  251 
The Flixabi® entry model (Table 4) was associated with the least savings compared to the other models despite 252 
the 50% discounted price compared to other infliximab biosimilars. This may be due to the fact that the 253 
infliximab market has been subjected to two established biosimilars and the majority of patients that were on 254 
Remicade® have already been switched to Remsima® and Inflectra®. This is supported by data from the 255 
Medicines Optimisation Dashboard that indicated that infliximab biosimilars utilisation ranged 0-49% in 14 256 
Trusts, 50-89% in 54 Trusts and 90-100% in 42 Trusts in April 2017 out of a total of 110 Trusts using 257 
infliximab in all specialities [35]. Therefore, it is likely that only a small proportion of patient on Remicade® 258 
would be eligible to be switched to Flixabi® and/or Flixabi® would be reserved for newly diagnosed patients. 259 
The Flixabi® model included a price reduction of existing infliximab biosimilars in response to increased 260 
competition. The impact of this scenario was higher in IBD than in RD since the proportion of patients treated 261 
with infliximab were much higher in IBD than those in RD. 262 
Etanercept is not licenced for use in IBD, therefore the results of the Erelzi® entry model was limited to RD. In 263 
this model, Erelzi® was assumed to be introduced at a 10% lower price than the currently available etanercept 264 
biosimilar (Benepali®). The budget impact of Erelzi® introduction was higher than that of Flixabi® since the 265 
utilisation of etanercept is much greater than infliximab in the RD market. The time of Erelzi® entry is critical in 266 
the analysis, since Benepali® was launched in 2016 and patients switching plans from Enbrel® to Benepali® was 267 
only started in 2017 (based on HCPs opinions). The medicines optimisation dashboard data indicated that 268 
etanercept biosimilars utilisation ranged 0-49% in 43 Trusts, 50-89% in 37 Trusts and 90-100% in 24 Trusts in 269 
April 2017 out of a total of 104 Trusts using etanercept in all specialities [35]. This means unlike infliximab, 270 
there is more opportunity for competition between Benepali® and Erelzi® to be used in newly diagnosed patients 271 
and for switching existing patients on Enbrel®. We modelled that this greater competition in the etanercept 272 
market would lead to more price reductions which would affect the price of Enbrel®; the model suggests a fall of 273 
50% to remain competitive.  274 
The adalimumab biosimilars entry model was based on a mixture of the experience following the entry of the 275 
etanercept and infliximab biosimilars. Due to the similarity between etanercept and adalimumab in terms of 276 
being the market dominants in the RD market, having a similar market share, mode of administration in patient-277 
friendly devices and similar price per defined daily dose (before the entry of biosimilars), the entry price of 278 
these new biosimilars was modelled on that of Benepali®. As it is expected that the three adalimumab 279 
biosimilars will be introduced at the same time, this is likely to provoke competition between these biosimilars 280 
(themselves) and with the brand (Humira®) in a similar way to how the market reacted when Inflectra® and 281 
Remsima® were launched at the same time in March 2015. Therefore, the subsequent price reductions seen in 282 
the infliximab market was used to model the price changes following the introduction of the three adalimumab 283 
biosimilars. Moreover, previous prescribers’ experience with infliximab and etanercept biosimilars would be 284 
reflected in easier (smoother) and faster entry into adalimumab market than the entry of infliximab and 285 
etanercept biosimilars. 286 
Despite the differences between biosimilars and generic medicines in term of structure, development and 287 
authorisation, generic and biosimilars share the similar commercial concepts of being a less expensive copy, 288 
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marketed following the patent expiry of the reference medicine [45]. The rapid and dramatic entry of infliximab 289 
and etanercept biosimilars was similar to some extent the entry of generic medicines. Infliximab biosimilars 290 
dominated the infliximab market in RD and IBD specialities in 3 years and in our BIA, is expected to replace 291 
Remicade® completely in the next 1-2 years (Figures 1 and 2). The same situation could be applied for 292 
etanercept and adalimumab biosimilars. This utilisation trend and the market penetration of these biosimilars is 293 
similar to the entry of generic medicines in the statins market [46]. 294 
Several BIAs assessing the impact of the introduction of infliximab and etanercept biosimilars were found in the 295 
literature [17-25]. As these BIAs were conducted in different countries in Europe, the total spending on 296 
bDMARDs and bDMAIDs varies between countries and the comparisons between international budgets would 297 
be inappropriate. A study by Ruff et al., (2015) estimated the five-year budget impact of etanercept biosimilars 298 
in the UK would result in savings of £100-£260 million based on the assumption that the etanercept biosimilar 299 
(Benepali®) price would be between 10-25% lower than that of Enbrel® [23]. Although our BIA was based on 300 
three-year time horizon, a lower total figure was anticipated to be achieved (from our previous analysis which 301 
showed that Benepali® achieved £23.4 million in the first year [16]. The results of this analysis in the reference 302 
case showed savings of £48 million mainly from (Benepali®), since RD are higher users of etanercept than IBD, 303 
and anticipated savings from Erelzi® entry (Table 4). The Ruff et al., study, did not take into account the impact 304 
of the competition between the Enbrel® and Benepali®, nor the entry of further biosimilars that would stimulate 305 
more competition with further price reductions and subsequent savings. 306 
Kanters et al., study estimated the adoption of infliximab biosimilars over five years in RD and IBD in UK, 307 
Germany, France, Spain and Italy based on 2012/13 data. A relatively low number of clinicians from each of the 308 
five European countries participated in this Delphi survey [25]. For compatibility reasons, we compared our 309 
results with the UK results of this study. Kanters et al., forecasted that the UK uptake of all infliximab 310 
biosimilars would gradually increase from 0% at the beginning of the analyses (year 0) to 2.5% by year 5 in RD 311 
and 12.5% in IBD; prices were fixed during the study period for both reference and biosimilar infliximab. 312 
Biosimilar infliximab was set at 50% discount of Remicade® list price with expected savings from the entry of 313 
infliximab biosimilars in UK of £181 million in RD and £770 million in IBD over five years.  314 
Our results showed less savings were associated with the entry of infliximab biosimilars (£48 million from 315 
already in use biosimilars with further £2 million from the entry of the third biosimilar (Flixabi) in RD. This 316 
discrepancy between Kanters et al., study and our results could be attributed to a number of factors. Kanters et 317 
al., used market shares at 2012/13 that did not reflect the dynamic changes in the RD and IBD markets 318 
following the entry of Inflectra® and Remsima®. Furthermore, the prices used in Kanters et al., model were the 319 
list prices, which were fixed during the study period, the biosimilar price discount was overestimated at 50%, 320 
and did not take into account the competition between the brand and the biosimilars and subsequent price 321 
reductions. In contrast our model was based on real-life utilisation and price data reflecting market behaviour. 322 
Furthermore, the Kanters et al., study was based on Delphi survey results in 2015, when infliximab biosimilars 323 
had just been launched in the UK market and HCPs had a no or little experience with bDMARDs and bDMAIDs 324 
biosimilars. The Kanters et al., study also overestimated vedolizumab market share and suggested an abrupt 325 
entry of this molecule into the IBD market. Our study based on actual utilisation data showed that vedolizumab 326 
entry was gradual since its availability in 2014 (Figure 2).  327 
Severs et al., (2017) estimated the impact of the introduction of biosimilars in IBD (2015-2019) in Netherlands 328 
[47]. This BIA was based on Dutch data (prevalence and cost). Although this BIA expected a price reduction of 329 
Remicade® in response to biosimilars competition, they also expected a price reduction of reference adalimumab 330 
(Humira®) in response to the entry of infliximab biosimilars and potential switching from adalimumab to 331 
infliximab biosimilars. Furthermore, this BIA did not estimate the entry of adalimumab biosimilars or the entry 332 
of vedolizumab and golimumab, which our real-world data has shown to have a substantial impact on the IBD 333 
market. 334 
The strengths of this study are that it is the first to calculate the impact of the entry of adalimumab and new 335 
infliximab and etanercept biosimilars. Furthermore, the assumptions in the BIA models were based on 336 
retrospective real-life utilisation and prices data. As with all BIAs, our model had limitations. Whilst rituximab 337 
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is an option in the treatment of RD when other biologics have failed, there is no defined daily dose index for this 338 
molecule due to its highly-individualised utilisation and wide dosage ranges. Therefore, rituximab utilisation 339 
cannot be compared to other bDMARDs and has not been included in this BIA. The recent introduction of three 340 
rituximab biosimilars in 2017 in UK, will undoubtedly produce additional cost savings. The model assumptions 341 
were based on previous market performance and HCPs perspectives. With the plethora of biosimilars entering 342 
the marketing and experience with biosimilars increasing the market dynamics may change over the period of 343 
the BIA. Administration and therapy monitoring costs were not included (assumed to be the same) since no 344 
switching between different molecules was anticipated. Although we acknowledged that there may be hidden 345 
administrative cost associated with switching and registering patients on disease registries as recommended by 346 
the National Rheumatoid Arthritis Society [48]. 347 
5. Conclusion 348 
According to this BIA, the introduction of new infliximab, etanercept and adalimumab biosimilars will be 349 
associated with considerable cost savings and have a substantial favourable impact on the UK NHS budget. The 350 
number of biosimilars and time of entry of is critical to create competition that leads to more cost savings. 351 
Despite the potential increase in the number of biosimilars, the use of reference bDMARDs/bDMAIDs not 352 
subjected to biosimilars competition is likely to continue to increase and offset some of the savings produced by 353 
biosimilars. 354 
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